News

The global CARES phase 3 clinical programme has shown that treatment with anselamimab, a potential first-in-class anti-fibril therapy, resulted in nominally…

AbstractIntroductionBlack individuals have significantly lower serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels than White individuals in the…

AbstractBackgroundPlasma transthyretin (TTR) is routinely quantified in clinical laboratories, yet the structural heterogeneity of circulating TTR and its potential…

Monitoring success in AL amyloidosis is a long-term journey. Managing the disease involves keeping a close eye on two different timelines: the speed of the “factory…

Increased levels of neurofilament light chain (NfL), a marker of nerve damage, are associated with more severe neurological symptoms in people with hereditary…

Potential antibody therapies from AstraZeneca and Regeneron for light chain (AL) amyloidosis had new data at ASCO, raising the prospect of new treatments for the…

AbstractWild-type transthyretin amyloid (ATTRwt) amyloidosis is a systemic, progressive disease that often affects older adults and is characterized by ATTRwt…

Cardiac amyloidosis is an increasingly recognized infiltrative cardiomyopathy characterized by extracellular deposition of misfolded amyloid fibrils within the…

AbstractAims: Eplontersen is an antisense oligonucleotide that suppresses hepatic production of circulating transthyretin (TTR) by targeting TTR mRNA. We present…

BACKGROUND: Acoramidis, an oral transthyretin stabilizer that achieves near-complete (≥90%) transthyretin stabilization, demonstrated significant clinical benefit…